We are resuming the registration of RSV in SIRI to monitor, together with the Public Health Agency of Sweden, the effectiveness of preventive treatment with monoclonal antibodies for children under three years of age. At the same time, we have conducted a review with the Public Health Agency of Sweden on how influenza and COVID-19 are registered.
RS Virus
Personal Data
- The care episode must start no earlier than 2025-09-01, and the patient must be at most three years old, calculated from the start of the care episode.
Background
The following questions must be answered:
- RSV vaccination during pregnancy (more than two weeks before delivery)?
- Has the child received preventive treatment with monoclonal antibodies this season (September–April)?
Follow-up question if the second question is answered “yes”:
- Date of monoclonal antibody treatment (usually the date of birth):
Risk Groups (compared to risk groups for influenza and COVID-19):
- Removed: People 65 years and older, Pregnant women, and Hypertension
- Changed: Children under 3 years, born prematurely (before gestational week 35) to (before gestational week 32)
- Added: Congenital esophageal atresia or diaphragmatic hernia and born before gestational week 26
Influenza
Antiviral Treatment
- Tamiflu changed to “Oseltamivir/Tamiflu”
- Baloxavir marboxil added
COVID-19
- Question about vaccination removed
Medications
- Vitamin C, Lopinavir, and Darunavir removed
- Nirmatrelvir/Ritonavir added